Anyone investing heavily this year??
- Thread starter rph2005
- Start date
What do you guys think about these two brothers:
Stock up with Larry
Kenan Grace
Stock up with Larry
Kenan Grace
i watch kenan
i check in on larry from time to time he seems to be a good brother
Apple loves to run back down to the 130's during a sell off, I'd wait until then.
Reminds me of Nike at times.
Long term doesnt mean much, apple is saying lack of supplies is the only reason,
they are taking this fourth qtr hit..
and thats not going to last forever....hopefully
lol
yep i agree
but i did just open a small position just to keep it on my radar
i'll load up on the big dip
$PROG Conference 10/29 ( DD)
Potential Squeeze With DD
Ok I will try to stay on track with this DD. Started looking into this conference coming up new week and I found some new exciting stuff about Progenity. As I have stated in past DDs, I am a pharmacist so I like drugs, drugs are my entire livelihood. I already mentioned Progenity's oral Adalimumab (Humira) candidate for ulcerative colitis (UC) but now we will move on to another drug class.
The other candidate mentioned on the page from their website link above is for PGN-OB2 - A Glucagon-Like Peptide (GLP) 1 Receptor Agonist. This class of medications is very different from biologics for UC (I see a huge potential for so many classes in between these classes). GLP-1 receptor agonists are injectable medications that have great data for type 2 diabetes as well as weight loss. These medications are also gaining a lot of traction for improving heart failure outcomes ($80 Billion markets)
One of the more recently developed mainstream heart failure medications is Novartis's Entresto with $2.5 Billion in sales in 2020. There are many different classes of medications but heart failure follows a long treatment algorithm with a multi-modal approach so these can all be additive therapies.
Onto the good stuff.
At this conference next Friday at 9:35 AM Eastern Time, Christopher Wahl, MD, MBA, CEO, and VP of Strategy and Operations of Progenity will be meeting at the Partnerships in Drug Delivery (PODD) Conference. The section with Dr. Wahl will include the Director of Oral Delivery Technologies from Novo Nordisk Stephen Buckley as well as the founders of Biograil APS and Vivtex. Quick google searches show that Biograil and Vivtex appear to be competitors of Progenity striving to develop technology for the administration of oral biologic medications. Biograil appears to have a partnership with Janssen in developing this technology but I could not find any patents currently issued to either of these companies and they have both not provided a news release since 2020.
So why did I mention GLP-1 receptor agonists and why is it important that Novo Nordisk will be at the table with Progenity? In November 2020, Novo Nordisk acquired a company developing a proprietary oral drug delivery system for their GLP-1 receptor agonist semaglutide (Rybelsus).
Since everyone is going to scroll to the bottom for the summary here it is. This acquisition was for $1.8 billion including any future royalties when Emisphere (EMIS) had a market cap of $673 Million at the time of acquisition.
Novo Nordisk put a price tag of close to $2 billion for a single pipeline item in Progenity's vast patent portfolio. Novo Nordisk will also be at a Partnership Conference with Progenity next Friday at the market open. Do with this information what you want.
Bullish. Not financial advice
I posted links but they were stopping my post from going through because I suck at Reddit.
Original Post
Potential Squeeze With DD
Ok I will try to stay on track with this DD. Started looking into this conference coming up new week and I found some new exciting stuff about Progenity. As I have stated in past DDs, I am a pharmacist so I like drugs, drugs are my entire livelihood. I already mentioned Progenity's oral Adalimumab (Humira) candidate for ulcerative colitis (UC) but now we will move on to another drug class.
The other candidate mentioned on the page from their website link above is for PGN-OB2 - A Glucagon-Like Peptide (GLP) 1 Receptor Agonist. This class of medications is very different from biologics for UC (I see a huge potential for so many classes in between these classes). GLP-1 receptor agonists are injectable medications that have great data for type 2 diabetes as well as weight loss. These medications are also gaining a lot of traction for improving heart failure outcomes ($80 Billion markets)
One of the more recently developed mainstream heart failure medications is Novartis's Entresto with $2.5 Billion in sales in 2020. There are many different classes of medications but heart failure follows a long treatment algorithm with a multi-modal approach so these can all be additive therapies.
Onto the good stuff.
At this conference next Friday at 9:35 AM Eastern Time, Christopher Wahl, MD, MBA, CEO, and VP of Strategy and Operations of Progenity will be meeting at the Partnerships in Drug Delivery (PODD) Conference. The section with Dr. Wahl will include the Director of Oral Delivery Technologies from Novo Nordisk Stephen Buckley as well as the founders of Biograil APS and Vivtex. Quick google searches show that Biograil and Vivtex appear to be competitors of Progenity striving to develop technology for the administration of oral biologic medications. Biograil appears to have a partnership with Janssen in developing this technology but I could not find any patents currently issued to either of these companies and they have both not provided a news release since 2020.
So why did I mention GLP-1 receptor agonists and why is it important that Novo Nordisk will be at the table with Progenity? In November 2020, Novo Nordisk acquired a company developing a proprietary oral drug delivery system for their GLP-1 receptor agonist semaglutide (Rybelsus).
Since everyone is going to scroll to the bottom for the summary here it is. This acquisition was for $1.8 billion including any future royalties when Emisphere (EMIS) had a market cap of $673 Million at the time of acquisition.
Novo Nordisk put a price tag of close to $2 billion for a single pipeline item in Progenity's vast patent portfolio. Novo Nordisk will also be at a Partnership Conference with Progenity next Friday at the market open. Do with this information what you want.
Bullish. Not financial advice
I posted links but they were stopping my post from going through because I suck at Reddit.
Original Post
$SOFI
My bad fellas...lol Got to many threads open lol
The same people that buy it $500. A lot of long-term investors invest in the market regardless of the prices (buying partial).
the chart is going crazy after hours$TSLA again.
We were considering the 1225 call right before close, but didn't buy.
I noticed, but I dont trade OTC. I saw the commercial with Brady in it the other day. They are really making a push.
Yea. They really pushing to go public again.
probably the deal they made with Tesla
it was moving before the deal, but ppl started back traveling and renting.
I pray none of u got caught up in this.
I'm sure alot of other people woke up pissed this morning.....
www.forbes.com
finance.yahoo.com
I'm sure alot of other people woke up pissed this morning.....
Viral Squid Game Cryptocurrency Crashes 100% In Minutes After Founders Reportedly Run Away With $2.5 Million
Amid a days-long retail trading frenzy, the Squid Game-inspired token skyrocketed as much as 310,000%.
www.forbes.com
Squid Game Is Memecoin Warning With Wipeout After 230,000% Gain
(Bloomberg) -- Most Read from BloombergInto the Metaverse: Where Crypto, Gaming and Capitalism CollideCan a New Mayor Fix Seattle’s Downtown?In Minneapolis Election, the Future of Policing Is at StakeThe Terrifying Rise of Haunted TourismThe Best New Restaurants in Washington, Chosen by Top...
I been following here and there (still mad that I missed the run up on $CAR over the past year == $30 to $170
) and bought a few shares last week off the strength of this dudes analysis..Similar threads
